Biology Reference
In-Depth Information
13. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer.
Nat Rev Cancer 2006; 6 :764-75.
14. Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA, Sloane BF. Tumor progres-
sion and angiogenesis: cathepsin B & Co. Biochem Cell Biol 1996; 74 :799-810.
15. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, et al. Prognostic
significance of cathepsins B and L in primary human breast cancer. J Clin Oncol
1998; 16 :1013-21.
16. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F, et al. Prognostic im-
pact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activa-
tor inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of
adjuvant systemic therapy. Clin Cancer Res 2001; 7 :2757-64.
17. Jagodic M, Vrhovec I, Borstnar S, Cufer T. Prognostic and predictive value of cathep-
sins D and L in operable breast cancer patients. Neoplasma 2005; 52 :1-9.
18. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet JP, et al. Biological and
clinical significance of cathepsin D in breast cancer metastasis. StemCells 1996; 14 :642-50.
19. Schneider C, Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis
Rev 2011; 30 :277-94.
20. Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in
hormonal cancer progression. Front Biosci (Schol Ed) 2011;
:788-96.
21. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell
metabolism? Oncotarget 2010; 1 :734-40.
22. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phospholipase A2 as a
target of therapy. Curr Opin Lipidol 2005; 16 :442-6.
23. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine
switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase
activation and atherosclerotic plaque rupture by myeloperoxidase.
3
J Biol Chem
2001; 276 :41279-87.
24. White H. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the
potential to improve patient outcomes. Curr Opin Cardiol 2010; 25 :299-301.
25. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-
converting enzyme: new class of orally active antihypertensive agents. Science
1977; 196 :441-4.
26. Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin,
in cardiovascular
injury:
from epithelium to endothelium. Biochem Pharmacol
2012; 83 :695-704.
27. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al.
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine,
and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334 :1011-7.
28. Orlowski RZ. Bortezomib and its role in the management of patients with multiple
myeloma. Expert Rev Anticancer Ther 2004; 4 :171-9.
29. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al.
Modulation of airway inflammation in cystic fibrosis. in vivo suppression of
interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombi-
nant secretory leukoprotease inhibitor. J Clin Invest 1992;
:1296-301.
30. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and
reduced risk of cancer in diabetic patients. BMJ 2005;
90
:1304-5.
31. Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, et al. PEGylated
DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Neoplasia 2007; 9 :927-37.
32. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al. Selective inhibition
of matrixmetalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer
Res 2009; 69 :1517-26.
330
Search WWH ::




Custom Search